Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Labopharm has reported that its once-daily tramadol product has received regulatory approval from the Korean and Australian regulatory agencies for the marketing and sale of company's pain treatment product in South Korea and Australia.
Subscribe to our email newsletter
The company expects its product to be launched in South Korea and Australia later this year.
James Howard-Tripp, president and CEO, Labopharm, said: “South Korea and Australia are important components of the global commercialization plan for our product. We are now working with our marketing partners in both countries towards the launches of our product later in 2008.”